Europe - FRA:22UA - US09075V1026 - ADR
Taking everything into account, 22UA scores 3 out of 10 in our fundamental rating. 22UA was compared to 77 industry peers in the Biotechnology industry. The financial health of 22UA is average, but there are quite some concerns on its profitability. 22UA is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -1.6% | ||
ROE | -1.87% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 84.15% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Altman-Z | 5.87 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.61 | ||
Quick Ratio | 8.48 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
FRA:22UA (9/25/2025, 7:00:00 PM)
83.7
-0.65 (-0.77%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 6.99 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.09 | ||
P/tB | 1.21 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -1.6% | ||
ROE | -1.87% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 84.15% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 270.61% | ||
Cap/Sales | 28.56% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 8.61 | ||
Quick Ratio | 8.48 | ||
Altman-Z | 5.87 |